A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

M. Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, Russell Szmulewitz, Thomas Powles, Roberto Pili, Justine Yang Bruce, Ulka Vaishampayan, James Larkin, Brad Rosbrook, Erjian Wang, Danielle Murphy, Panpan Wang, Maria Josè Lechuga, Olga Valota, Dale R. Shepard

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Lessons Learned: The combination of axitinib and crizotinib has a manageable safety and tolerability profile, consistent with the profiles of the individual agents when administered as monotherapy. The antitumor activity reported here for the combination axitinib/crizotinib does not support further study of this combination treatment in metastatic renal cell carcinoma given the current treatment landscape. Background: Vascular endothelial growth factor (VEGF) inhibitors have been successfully used to treat metastatic renal cell carcinoma (mRCC); however, resistance eventually develops in most cases. Tyrosine protein kinase Met (MET) expression increases following VEGF inhibition, and inhibition of both has shown additive effects in controlling tumor growth and metastasis. We therefore conducted a study of axitinib plus crizotinib in advanced solid tumors and mRCC. Methods: This phase Ib study included a dose-escalation phase (starting doses: axitinib 3 mg plus crizotinib 200 mg) to estimate maximum tolerated dose (MTD) in patients with solid tumors and a dose-expansion phase to examine preliminary efficacy in treatment-naïve patients with mRCC. Safety, pharmacokinetics, and biomarkers were also assessed. Results: No patients in the dose-escalation phase (n = 22) experienced dose-limiting toxicity; MTD was estimated to be axitinib 5 mg plus crizotinib 250 mg. The most common grade ≥3 adverse events were hypertension (18.2%) and fatigue (9.1%). In the dose-expansion phase, overall response rate was 30% (95% confidence interval [CI], 11.9–54.3), and progression-free survival was 5.6 months (95% CI, 3.5–not reached). Conclusion: The combination of axitinib plus crizotinib, at estimated MTD, had a manageable safety profile and showed evidence of modest antitumor activity in mRCC.

Original languageEnglish (US)
Pages (from-to)1151-e817
Issue number9
StatePublished - Sep 1 2019

Bibliographical note

Funding Information:
This study was sponsored by Pfizer Inc. Medical writing support was provided by Charles Cheng of Engage Scientific Solutions and was funded by Pfizer Inc.

PubMed: MeSH publication types

  • Clinical Trial, Phase I
  • Journal Article
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors'. Together they form a unique fingerprint.

Cite this